Lista de obras - Melissa Bersanelli - Dominio Público Uruguay

"Finding NEMO" in NRAS-mutant melanoma: a step towards a sequential strategy?

artículo científico publicado en 2017

A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?

scientific article published on 01 March 2020

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

artículo científico publicado en 2019

A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients

scientific article published on 01 August 2019

An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study

artículo científico publicado en 2020

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

artículo científico publicado en 2011

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-r

scientific article published on 04 February 2020

Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study

artículo científico publicado en 2020

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

artículo científico publicado en 2020

Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients

article

Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?

Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

artículo científico publicado en 2020

Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

artículo científico publicado en 2014

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

artículo científico publicado en 2017

COVID-19 and the newly rediscovered multidisciplinarity

artículo científico publicado en 2020

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

artículo científico publicado en 2017

Cabozantinib in renal cell carcinoma: only a METEOR or a rising star?

artículo científico publicado en 2016

Chemotherapy in metastatic renal cell carcinoma today? A systematic review

artículo científico publicado en 2013

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

artículo científico publicado en 2020

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

scientific article published on 22 February 2019

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

artículo científico publicado en 2018

Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy

scientific article published on 15 September 2020

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.

artículo científico publicado en 2017

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma.

artículo científico publicado en 2017

Combination therapy in kidney cancer: the next revolution?

artículo científico publicado en 2015

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

artículo científico publicado en 2020

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

artículo científico publicado en 2018

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

scientific article published on 21 February 2019

Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab

artículo científico publicado en 2019

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.

artículo científico publicado en 2014

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

artículo científico publicado en 2020

Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years

artículo científico publicado en 2020

Endometrial metastasis of lung adenocarcinoma: a case report

artículo científico publicado en 2011

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

artículo científico publicado en 2020

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy

artículo científico publicado en 2016

Family history of cancer and DNA damage response genes: Two sides of the same coin?

scientific article published on 08 December 2018

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study

artículo científico publicado en 2018

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

artículo científico publicado en 2017

First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.

artículo científico publicado en 2016

From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.

artículo científico publicado en 2017

Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis

Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.

artículo científico publicado en 2014

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study

Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma

artículo científico publicado en 2019

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

artículo científico publicado en 2020

Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients

artículo científico publicado en 2020

Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts.

artículo científico publicado en 2017

Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis

scientific article published on 19 January 2020

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

artículo científico publicado en 2020

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer

artículo científico publicado en 2016

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.

artículo científico publicado en 2016

Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?

artículo científico publicado en 2017

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

artículo científico publicado en 2016

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

artículo científico publicado en 2020

Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

artículo científico publicado en 2018

Lymph node ratio improves TNM and Astler-Coller's assessment of colorectal cancer prognosis: an analysis of 761 node positive cases.

artículo científico publicado en 2014

MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma

artículo científico publicado en 2020

Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions

artículo científico publicado en 2020

Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

scientific article published on 19 July 2019

Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma

scientific article published on 21 November 2019

Non-clear-cell renal carcinoma therapy: handle with care

artículo científico publicado en 2016

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.

artículo científico publicado en 2015

Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review

artículo científico publicado en 2016

Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study

scientific article published on 13 December 2019

Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptions

artículo científico publicado en 2019

Patient performance status and cancer immunotherapy efficacy: a meta-analysis

scientific article published on 20 August 2018

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

scientific article published on 26 May 2020

Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report.

artículo científico publicado en 2016

Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma

artículo científico publicado en 2020

Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review

artículo científico publicado en 2016

Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review

scientific article published on 24 October 2019

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy

artículo científico publicado en 2015

Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?

artículo científico

Retroperitoneal cystoadenocarcinoma: a case report with a literature review

Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis

artículo científico publicado en 2018

Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients.

artículo científico publicado en 2015

Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the "embarrassment of riches"

artículo científico publicado en 2019

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

scientific article published on 10 February 2019

Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer

artículo científico publicado en 2020

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date

article

State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough

artículo científico publicado en 2019

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

artículo científico publicado en 2020

Systemic adjuvant therapies in renal cell carcinoma

artículo científico publicado en 2012

The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.

artículo científico publicado en 2016

The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors

artículo científico publicado en 2020

The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes

scientific article published on 01 June 2019

The latest developments in biomarkers predicting response to immunotherapy

artículo científico publicado en 2022

The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade

artículo científico publicado en 2017

The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma

artículo científico publicado en 2020

The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma

artículo científico publicado en 2018

The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a "transcriptomic compass"?

artículo científico publicado en 2019

Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study

artículo científico publicado en 2019

Tumour mutational burden as a driver for treatment choice in resistant tumours (and beyond)

scientific article published on 10 September 2020

Upfront Chemohormonal Therapy for Prostate Cancer: Neutropenia and G-CSF Use

artículo científico publicado en 2016

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population

artículo científico publicado en 2018

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.

artículo científico publicado en 2017

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

artículo científico publicado en 2019

[Influenza vaccination in advanced cancer patients undergoing immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: what data do we have for the clinical recommendation?]

artículo científico publicado en 2018

Lista de obras de Melissa Bersanelli

"Finding NEMO" in NRAS-mutant melanoma: a step towards a sequential strategy?

A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients

An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-r

Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients

Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?

Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

COVID-19 and the newly rediscovered multidisciplinarity

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

Cabozantinib in renal cell carcinoma: only a METEOR or a rising star?

Chemotherapy in metastatic renal cell carcinoma today? A systematic review

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma.

Combination therapy in kidney cancer: the next revolution?

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years

Endometrial metastasis of lung adenocarcinoma: a case report

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy

Family history of cancer and DNA damage response genes: Two sides of the same coin?

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.

From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.

Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis

Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study

Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients

Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts.

Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.

Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

Lymph node ratio improves TNM and Astler-Coller's assessment of colorectal cancer prognosis: an analysis of 761 node positive cases.

MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma

Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions

Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma

Non-clear-cell renal carcinoma therapy: handle with care

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.

Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review

Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study

Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptions

Patient performance status and cancer immunotherapy efficacy: a meta-analysis

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report.

Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma

Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review

Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy

Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?

Retroperitoneal cystoadenocarcinoma: a case report with a literature review

Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis

Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients.

Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the "embarrassment of riches"

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis